Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA.
Pharmacogenomics. 2011 Feb;12(2):267-75. doi: 10.2217/pgs.10.186.
Although cancer treatment with radiation can produce high cure rates, adverse effects often result from radiotherapy. These toxicities are manifested as damage to normal tissues and organs in the radiation field. In recognition of the substantial variation in the intrinsic response of individuals to radiation, an effort began approximately 10 years ago to discover the genetic markers, primarily SNPs, which are associated with susceptibility for the development of these adverse responses to radiation therapy. The goal of this research is to identify the SNPs that could serve as the basis of an assay to predict which cancer patients are most likely to develop complications resulting from radiotherapy. This would permit personalization and optimization of the treatment plan for each cancer patient.
虽然癌症的放射治疗可以产生很高的治愈率，但放射治疗也常常会产生不良反应。这些毒性表现为放射野内正常组织和器官的损伤。鉴于个体对辐射的内在反应存在很大差异，大约 10 年前，人们开始努力寻找与这些放射治疗不良反应易感性相关的遗传标记物，主要是单核苷酸多态性（SNP）。这项研究的目的是确定可以作为检测基础的 SNP，以预测哪些癌症患者最有可能因放射治疗而产生并发症。这将允许为每个癌症患者制定个性化和优化的治疗计划。
